Eli Lil­ly, Boehringer In­gel­heim tout piv­otal heart fail­ure win for Jar­diance, po­ten­tial­ly set­ting up a No­var­tis show­down

The ma­jor mar­ket for chron­ic heart fail­ure — un­til re­cent­ly an in­di­ca­tion with­out a sin­gle ap­proved ther­a­py — has evolved in­to a horse race in re­cent months with some big-name drug­mak­ers in the lead. A few steps be­hind No­var­tis, Eli Lil­ly and Boehringer In­gel­heim are tout­ing new da­ta for SGLT2 in­hibitor Jar­diance they think will get the drug across the fin­ish line.

Jar­diance aced the pri­ma­ry end­point in a piv­otal out­comes tri­al in heart fail­ure pa­tients with a pre­served ejec­tion frac­tion (HF­pEF) with or with­out Type 2 di­a­betes, a ma­jor car­dio mar­ket which No­var­tis’ En­tresto cracked open ear­li­er this year af­ter an FDA ap­proval, the part­ners said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER